BNP Paribas Financial Markets Trims Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

BNP Paribas Financial Markets reduced its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 55.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,355 shares of the biotechnology company’s stock after selling 7,874 shares during the quarter. BNP Paribas Financial Markets’ holdings in Aldeyra Therapeutics were worth $32,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Aldeyra Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company’s stock valued at $5,588,000 after buying an additional 4,927 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Aldeyra Therapeutics by 21.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 735,763 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 131,722 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at approximately $3,628,000. ADAR1 Capital Management LLC increased its position in shares of Aldeyra Therapeutics by 114.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 647,960 shares of the biotechnology company’s stock valued at $3,233,000 after buying an additional 345,748 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Aldeyra Therapeutics by 4.3% in the fourth quarter. Northern Trust Corp now owns 405,517 shares of the biotechnology company’s stock valued at $2,024,000 after buying an additional 16,894 shares in the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. BTIG Research cut their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, April 7th. Wall Street Zen upgraded Aldeyra Therapeutics to a “sell” rating in a research report on Wednesday, May 21st. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, May 19th.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ:ALDX opened at $2.47 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The business’s 50 day moving average price is $2.43 and its 200-day moving average price is $4.48. The firm has a market capitalization of $147.94 million, a PE ratio of -2.55 and a beta of 0.92. Aldeyra Therapeutics, Inc has a 1 year low of $1.14 and a 1 year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08. As a group, equities research analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business’s stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. The trade was a 36.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.60% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.